Conference Track

Improving HCV Therapy in 2006

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Combination of Peginterferon alfa-2a Plus Ribavirin Active in Liver Transplant Recipients With Recurrent HCV
24-Week Peginterferon alfa-2a Plus Ribavirin Regimen Appears Effective in Patients With Genotype 1 or 4 HCV Who Respond Early to Treatment
12 Weeks of Peginterferon alfa-2a Plus Ribavirin Effective, Well Tolerated in Patients Previously Failing Peginterferon alfa-2b Plus Ribavirin
Wild-Type HCV Predominates Over VX-950–Resistant Variants Upon Removal of Drug-Induced Selective Pressure
Liver Transplant a Viable Treatment Option for HIV Patients Coinfected With Hepatitis B and C
Valopicitabine/Peginterferon alfa-2a More Effective Than Peginterferon alfa-2a/Ribavirin at Producing Virologic Response in HCV Genotype 1–Infected Prior Nonresponders
24-Week Treatment With Peginterferon alfa-2b Plus Ribavirin Effective for Patients With HCV Genotype 2/3
SCH 503034 Plus Peginterferon alfa-2b Safe, Effective in Prior Peginterferon Nonresponders With HCV Genotype 1
Low-Dose (400 mg/day) Ribavirin in Combination With Peginterferon alfa-2a Effectively Treats HCV Genotype 2 and 3 Patients
Albumin Interferon alfa-2b Safe and Effective in Interferon-Refractory Patients
48 Weeks of Peginterferon alfa-2b Plus Ribavirin More Effective Than Shorter Treatment for Most Patients With HCV Genotype 1
Similar Outcomes With Peginterferon alfa-2a Plus Ribavirin in Community Practice vs Clinical Trial Setting in Patients With Chronic HCV Genotype 1 Infection
R1626 Shows Promise for Treatment of HCV Genotype 1 Patients
Albumin Interferon alfa-2b Comparable in Safety and Efficacy for HCV Genotype 1 Infection to Peginterferon alfa 2-a when Combined With Weight-based Ribavirin
24 Weeks of Peginterferon alfa-2a Plus Ribavirin More Effective Than 16 Weeks in Patients With HCV Genotype 2 or 3
Valopicitabine + Peginterferon alfa-2a Produces Potent and Early Virologic Response in Treatment-Naive Patients With HCV Genotype 1
Combination Treatment With VX-950 Plus Peginterferon alfa-2a Highly Potent, Well Tolerated in Treatment-Naive Patients With HCV Genotype 1
Delayed Relapse Rare in HCV Patients Who Achieve Sustained Virologic Response With Interferon alfa-2b ± Ribavirin
Interim Analysis Demonstrates Safety and Efficacy of Eltrombopag for Treatment of HCV-Related Thrombocytopenia
Viramidine Associated With Significantly Lower Rate of Anemia Compared With Ribavirin in Treatment-Naive Patients With HCV

Expert Analysis

Improving HCV Therapy in 2006

Faculty:

Nezam H. Afdhal, MD, FRCPI
Peter Ferenci, MD
Stephanos J. Hadziyannis, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss data from studies of novel drugs for the treatment of patients with hepatitis C virus (HCV)
Recount strategies for improving the current treatment and outcomes of patients with HCV
Review the results of studies evaluating the treatment of nonresponders and patients with HCV genotype 1

CREDIT INFORMATION

Release Date: June 29, 2006

Expiration Date: June 28, 2007

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.